Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Nektar Therapeutics (NASDAQ:NKTR)

11.94
Delayed Data
As of Feb 05
 +0.25 / +2.14%
Today’s Change
9.16
Today|||52-Week Range
17.55
-29.14%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.6B

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. The company provides small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. The company was founded in 1990 and is headquartered in San Francisco, CA.

Contact Information

Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco California 94158
P:(415) 482-5300
Investor Relations:
(415) 482-5585

Employees

Shareholders

Mutual fund holders82.24%
Other institutional24.01%
Individual stakeholders1.89%

Top Executives

Howard W. RobinPresident, Chief Executive Officer & Director
John NicholsonChief Financial Officer & Senior Vice President
Stephen K. DobersteinChief Scientific Officer & Senior Vice President
Ivan P. GergelChief Medical Officer & Senior VP-Drug Development
Mary TagliaferriVice President-Clinical Development